Eden is providing access to a new way for individuals to explore GLP-1 therapy: a compounded semaglutide gummy, available ...

A new study adds to a growing body of evidence that semaglutide has benefits other than weight loss or controlling diabetes.

A Phase 3 clinical trial found that injections of the semaglutide medication once weekly reduced the risk of kidney disease worsening by 24% in people who also had diabetes. It also reduced the ...

announced the expansion of its industry-leading formulary of more than a dozen medications to include compounded oral semaglutide dissolving tablets. This needle-free option requires no ...

Novo Nordisk has struggled to meet the demand for its blockbuster GLP-1 receptor agonists (GLP-1RA) Wegovy and Ozempic (semaglutide ... The company sold its pen needles and blood glucose ...

Semaglutide is a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor mimicking its activity. GLP-1 is an incretin hormone and enterogastrone that stimulates insulin ...